Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.

Autor: Fiala O; Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital Pilsen, Charles University, Alej Svobody 80, 304 60, Pilsen, Czech Republic. fialao@fnplzen.cz.; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. fialao@fnplzen.cz., Buti S; Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Takeshita H; Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Okada Y; Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15, Bologna, Italy., Palacios GA; Department of Medical Oncology, Institutd' Investigació Biomèdica Sant Pau, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain., Dionese M; Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128, Padua, Italy., Scagliarini S; UOC Di Oncologia, Azienda Ospedaliera Di Rilievo Nazionale Cardarelli Di Napoli, Naples, Italy., Büttner T; Department of Urology, University Hospital Bonn (UKB), 53127, Bonn, Germany., Fornarini G; IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Myint ZW; Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA., Galli L; Oncology Unit 2, University Hospital of Pisa, 56126, Pisa, Italy., Souza VC; Hospital São Rafael Oncologia D'Or, Salvador, BA, Brazil.; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil., Pichler R; Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Quiroga MNG; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Hospital Angel Roffo, Buenos Aires, CABA, Argentina., Gilbert D; University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA., Popovic L; Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Mammone G; Department of Radiological, Oncological and Anatomo-Pathological Science, Sapienza University of Rome, Viale Regina Elena 324, 00185, Rome, Italy., Berardi R; Department of Medical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti Delle Marche, Ancona, Italy., Crabb SJ; Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain., Freitas M; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Centro de Pesquisas Oncológicas - CEPON, Florianópolis, SC, Brazil., Luz M; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Hospital Erasto Gaertner, Curitiba, PR, Brazil., Iacovelli R; Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Calabrò F; Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy., Tural D; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Zuhuratbaba District, Tevfik Saglam St. No: 11, Bakirkoy, Istanbul, Turkey., Atzori F; Unità Di Oncologia Medica, Azienda Ospedaliero Universitaria Di Cagliari, Cagliari, Italy., Küronya Z; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary., Chiari R; UOC Oncologia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano, Italy., Campos S; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Centro Oncologico Estatal 'Dr José Luis Barrera Franco' del ISSEMYM, Toluca de Lerdo, Mexico., Caffo O; Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy., Fay AP; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Pontificia Universidade Católica Do Rio Grande Do Sul - PUCRS, Porto Alegre, RS, Brazil., Kucharz J; Department of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Zucali PA; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Rinck JA; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Hospital AC Camargo, São Paulo, SP, Brazil., Zeppellini A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bastos DA; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Department of Oncology, Hospital Sírio-Libanês, São Paulo, SP, Brazil., Aurilio G; Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy., Mota A; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Clínica AMO, Salvador, BA, Brazil., Trindade K; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncologia D'Or, Fortaleza, CE, Brazil., Ortega C; Division of Oncology, Institute for Cancer Research and Treatment, Asl Cn2 Alba-Brà, 12051, Alba-Brà, Italy., Sade JP; Instituto Alexander Fleming, Buenos Aires, CABA, Argentina., Rizzo M; Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Piazza G. Cesare 11, 70124, Bari, Italy., Vau N; Urologic Oncology, Champalimaud Clinical Center, 1400-038, Lisbon, Portugal., Giannatempo P; Dipartimento Di Oncologia Medica, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Barillas A; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Clinicas Medicas Especializadas NUCARE, Guatemala City, Guatemala., Monteiro FSM; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Oncology and Hematology Department, Hospital Santa Lucia, SHLS 716 Cj. C, Brasília, DF, 70390-700, Brazil., Dauster B; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Hospital Sao Rafael, Salvador, BA, Brazil., Cattrini C; Department of Medical Oncology, 'Maggiore Della Carità' University Hospital, 28100, Novara, Italy., Nogueira L; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Universidade Federal de Minas Gerais - UFMG, Belo Horizonte, MG, Brazil., de Carvalho Fernandes R; Hospital Santa Casa de Sao Paulo, São Paulo, SP, Brazil., Seront E; Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium., Aceituno LG; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Clinica Medica Especializada en Oncologia Medica, Guatemala City, Guatemala., Grillone F; SOC Oncologia Medica, Azienda Ospedaliera 'Pugliese -Ciaccio', Catanzaro, Italy., Cutuli HJ; Hospital Sirio Libanes, Buenos Aires, CABA, Argentina., Fernandez M; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Fundacion Centro Oncologico de Integracion Regional - COIR, Mendoza, Argentina., Bassanelli M; Medical Oncology, 1-IRCCS Regina Elena National Cancer Institute, Rome, Italy., Roviello G; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy., Abahssain H; Medical Oncology Unit, National Institute of Oncology, Medicine and Pharmacy Faculty, Mohammed V University, Rabat, Morocco., Procopio G; Dipartimento Di Oncologia Medica, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.; Oncologia Medica, Ospedale Maggiore Di Cremona, Cremona, Italy., Milella M; Section of Oncology, Department of Medicine, School of Medicine and Verona University Hospital Trust, University of Verona, Verona, Italy., Kopecky J; Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Martignetti A; UOC Oncologia Medica, Ospedale Dell'alta Val D'Elsa - Usl sud est Toscana Area Senese, Poggibonsi, Italy., Messina C; Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy., Caitano M; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Hospital do Câncer Porto Dias - Rede Mater Dei de Saúde, Belém, PA, Brazil., Inman E; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; ONCOR Life Medical Center, Saltillo, Mexico., Kanesvaran R; National Cancer Centre Singapore, Singapore, Republic of Singapore., Herchenhorn D; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Instituto D'Or de Ensino E Pesquisa, Rio de Janeiro, RJ, Brazil., Santini D; Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy., Manneh R; Clinical Oncology, Sociedad de Oncología Y Hematología del Cesar, Valledupar, Colombia., Bisonni R; UOC Oncologia Medica, Ospedale A. Murri, Fermo, Italy., Zakopoulou R; 2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece., Mosca A; Department of Oncology Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy., Morelli F; Medical Oncology Unit, Gemelli Molise Hospital, Università Cattolica del Sacro Cuore, Campobasso, Italy., Maluf F; Hospital Beneficencia Portuguesa de São Paulo, São Paulo, SP, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Soares A; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Centro Paulista de Oncologia/Oncoclinicas, Sao Paulo, Brazil., Nunes F; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.; Clinica de Oncologia - Clion, Salvador, BA, Brazil., Pinto A; Medical Oncology Department, La Paz University Hospital, Madrid, Spain., Zgura A; Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, University of Medicine and Pharmacy, Bucharest, Romania., Incorvaia L; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Ansari J; Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates., Zabalza IO; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Landmesser J; Klinik Für Urologie, Ratzeburger Allee 160, 23538, Lübeck, Germany., Rizzo A; Struttura Semplice Dipartimentale Di Oncologia Medica Per La Presa in Carico Globale del Paziente Oncologico 'Don Tonino Bello', I.R.C.C.S. Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco 65, 70124, Bari, Italy., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Albertoni - 15, Bologna, Italy., Sorgentoni G; Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy., Battelli N; Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy., Porta C; Interdisciplinary Department of Medicine, University of Bari 'Aldo Moro', Bari, Italy., Bellmunt J; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Santoni M; Oncology Unit, Macerata Hospital, Via Santa Lucia 2, 62100, Macerata, Italy.
Jazyk: angličtina
Zdroj: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Nov; Vol. 72 (11), pp. 3665-3682. Date of Electronic Publication: 2023 Sep 07.
DOI: 10.1007/s00262-023-03518-z
Abstrakt: Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab.
Methods: We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model.
Results: A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival.
Conclusions: Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: